Modafinil — Provigil — and its R-enantiomer armodafinil — Nuvigil — are wake-promoting agents distinct from the amphetamine and methylphenidate stimulants. The mechanism is not fully characterized but involves weak DAT inhibition, histaminergic effects, orexinergic effects, and glutamate enhancement. The result is wakefulness promotion without the euphoric reinforcement of classic stimulants.
- Class
- Wake-promoting agents
- Mechanism
- Mechanism not fully understood: weak DAT inhibition, histaminergic and orexinergic effects, glutamate enhancement, GABA decrease. Wake-promoting without typical stimulant euphoria.
- Typical dose
- Modafinil 100-400 mg morning; armodafinil 150-250 mg morning
- Half-life
- Modafinil ~12 hours; armodafinil ~15 hours
- FDA indications
- Narcolepsy, OSA residual sleepiness despite CPAP, shift work sleep disorder
- Key adverse effects
- Headache, nausea, anxiety, insomnia (if late dosing), modest BP/HR elevation, rare serious skin reactions (Stevens-Johnson), psychiatric symptoms (rare)
- Representative agents
- Modafinil (Provigil), armodafinil (Nuvigil — R-enantiomer)
Black box: No FDA boxed warning (serious skin reactions — Stevens-Johnson syndrome/TEN — are a labeled Warning, not a boxed warning; discontinue at first sign of rash)
Schedule IV — lower abuse potential than amphetamines but not zero. Sometimes used off-label for ADHD, MDD-related fatigue, cognitive enhancement (controversial). Drug interaction: CYP3A4 induction reduces oral contraceptive efficacy.
Schedule IV — meaningfully lower abuse liability than amphetamines (Schedule II), but not zero. Some abuse occurs, particularly in academic and cognitive-enhancement contexts. Counsel about diversion in patients with substance use history.
Modafinil and armodafinil are wake-promoting agents — their mechanism produces alertness without the broad catecholamine surge of classic stimulants.
Mechanism note: Modafinil/armodafinil promote wakefulness through a gentler, more selective mechanism than classic stimulants — useful for sleep-disorder sleepiness and selected off-label fatigue/ADHD scenarios.
FDA indications are specific: narcolepsy (excessive daytime sleepiness), OSA residual sleepiness (in patients on optimized CPAP who still have impairing sleepiness), and shift work sleep disorder. These are the evidence-based, label-supported uses.
For OSA residual sleepiness, the prerequisite is "optimized CPAP." The patient with poor CPAP adherence or poorly titrated CPAP should have those addressed first; modafinil should not become a substitute for adequate OSA treatment.
- Cost
- Modafinil generic ~$30-80/month. Armodafinil (Nuvigil) generic ~$40-120/month. Brand forms substantially higher.
- Generic status
- Both generic.
- Formulary typical
- Generics Tier 2-3. PA often required, particularly for non-narcolepsy indications.
- Access friction
- Schedule IV. PA often requires documented narcolepsy or OSA on optimized CPAP. Off-label uses (ADHD, cognitive enhancement) often denied.
Prescriber tip: For OSA residual sleepiness, document CPAP adherence and titration before PA. Off-label ADHD use generally not covered.
Off-label uses include ADHD and cognitive enhancement in healthy individuals. Both are controversial. The ADHD evidence is mixed; modafinil is not FDA-approved for that indication. Cognitive enhancement in healthy individuals raises ethical and practical concerns and lacks robust efficacy data for sustained benefit.
Side effects: headache (most common), nausea, anxiety, insomnia if dosed too late in the day, modest BP/HR elevation. The rare serious adverse effect is severe skin reactions — Stevens-Johnson syndrome and TEN have been reported. Any rash on modafinil should prompt immediate discontinuation. CYP3A4 induction also reduces oral contraceptive efficacy — important counseling point.
For narcolepsy and OSA residual sleepiness, modafinil and armodafinil are the right tools. For ADHD and cognitive enhancement, the case for these agents is weaker than the marketing might suggest.